Methods | Prospective study, treatment in the better‐seeing eye | |
Participants | Country: Turkey Number of people randomised: 70 participants (35 ranibizumab, 35 grid laser) Average age: 64.6 ± 8.2 years ranibizumab; 63.8 ± 7.4 years laser Sex: 21% male ranibizumab, 18% male laser Inclusion criteria:
Exclusion criteria:
|
|
Interventions | Focal or grid laser photocoagulation treatment was performed in 35 participants and laser settings, including power, spot size, duration and number of burns, were recorded 35 participants received initial injection of ranibizumab 0.5 mg/0.05 mL. All participants of both groups received treatment in their better‐seeing eye. After the induction phase, the intravitreal injections were administered if any of the following changes were observed: presence of visual acuity loss; persistent or recurrent subretinal or intraretinal fluid. |
|
Outcomes | Group comparisons of absolute scores and mean changes from baseline scores at 6‐month visit were performed using analysis of the Turkish version of VFQ‐25; it has modifications to adjust for Turkish culture and lifestyle. | |
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | No data available |
Allocation concealment (selection bias) | Unclear risk | No data available |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | No data available |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | No data available |
Incomplete outcome data (attrition bias) All outcomes | Low risk | No loss to follow‐up reported |
Selective reporting (reporting bias) | Unclear risk | No specific statement nor protocol available |
Other bias | Low risk | No other bias identified |
Overall risk of bias | Unclear risk | Most items not reported |